Geoffrey R. Oxnard

992 total papers · 28.6k total citations
297 papers, 15.1k citations indexed

About

Geoffrey R. Oxnard is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, Geoffrey R. Oxnard has authored 297 papers receiving a total of 15.1k indexed citations (citations by other indexed papers that have themselves been cited), including 230 papers in Pulmonary and Respiratory Medicine, 157 papers in Cancer Research and 154 papers in Oncology. Recurrent topics in Geoffrey R. Oxnard's work include Lung Cancer Treatments and Mutations (198 papers), Cancer Genomics and Diagnostics (153 papers) and Colorectal Cancer Treatments and Studies (52 papers). Geoffrey R. Oxnard is often cited by papers focused on Lung Cancer Treatments and Mutations (198 papers), Cancer Genomics and Diagnostics (153 papers) and Colorectal Cancer Treatments and Studies (52 papers). Geoffrey R. Oxnard collaborates with scholars based in United States, South Korea and United Kingdom. Geoffrey R. Oxnard's co-authors include Pasi A. Jänne, Cloud P. Paweletz, Mark G. Kris, Vincent A. Miller, Suzanne E. Dahlberg, Marc Ladanyi, William Pao, Kenneth S. Thress, Maria E. Arcila and David M. Jackman and has published in prestigious journals such as Nature Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Geoffrey R. Oxnard

286 papers receiving 14.9k citations

Hit Papers

Acquired EGFR C797S mutat... 2010 2026 2015 2020 2015 2016 2018 2014 2018 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
    2015 1.2k citations Kenneth S. Thress, Cloud P. Paweletz et al. Nature Medicine profile →
  2. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
    2016 639 citations Geoffrey R. Oxnard, Kenneth S. Thress et al. Journal of Clinical Oncology profile →
  3. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
    2018 601 citations Jason D. Merker, Geoffrey R. Oxnard et al. Journal of Clinical Oncology profile →
  4. Noninvasive Detection of Response and Resistance in EGFR -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
    2014 589 citations Geoffrey R. Oxnard, Cloud P. Paweletz et al. Clinical Cancer Research profile →
  5. Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
    2018 509 citations Geoffrey R. Oxnard, Yuebi Hu et al. JAMA Oncology profile →
  6. MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
    2016 491 citations Mark M. Awad, Geoffrey R. Oxnard et al. Journal of Clinical Oncology profile →
  7. Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
    2010 484 citations Geoffrey R. Oxnard, Maria E. Arcila et al. Clinical Cancer Research profile →
  8. Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
    2011 474 citations Maria E. Arcila, Geoffrey R. Oxnard et al. Clinical Cancer Research profile →
  9. Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung Cancer
    2016 431 citations Adrian G. Sacher, Cloud P. Paweletz et al. JAMA Oncology profile →
  10. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
    2020 301 citations Geoffrey R. Oxnard, J.C.-H. Yang et al. Annals of Oncology profile →
  11. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
    2020 292 citations Lecia V. Sequist, Ji‐Youn Han et al. The Lancet Oncology profile →
  12. False-Positive Plasma Genotyping Due to Clonal Hematopoiesis
    2018 288 citations Yuebi Hu, Bryan C. Ulrich et al. Clinical Cancer Research profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Geoffrey R. Oxnard 11.1k 8.4k 6.2k 4.8k 1.7k 297 15.1k
Maria E. Arcila 10.6k 1.0× 8.7k 1.0× 4.7k 0.8× 5.7k 1.2× 1.8k 1.1× 251 15.6k
Sai‐Hong Ignatius Ou 14.0k 1.3× 11.7k 1.4× 3.5k 0.6× 5.5k 1.1× 1.6k 1.0× 348 17.5k
Marileila Varella‐Garcia 11.1k 1.0× 10.0k 1.2× 4.0k 0.6× 7.2k 1.5× 1.4k 0.8× 246 18.1k
Lucio Crinò 13.4k 1.2× 13.5k 1.6× 3.3k 0.5× 5.5k 1.1× 1.3k 0.7× 374 19.4k
Neal I. Lindeman 13.2k 1.2× 11.6k 1.4× 5.8k 0.9× 8.1k 1.7× 2.6k 1.5× 170 22.3k
Alexander Drilon 7.9k 0.7× 7.2k 0.9× 3.5k 0.6× 4.4k 0.9× 1.8k 1.1× 378 12.9k
Masahiro Fukuoka 16.7k 1.5× 15.2k 1.8× 3.3k 0.5× 6.1k 1.3× 956 0.6× 266 22.5k
Alice T. Shaw 18.3k 1.7× 15.8k 1.9× 5.8k 0.9× 9.6k 2.0× 2.3k 1.3× 332 24.9k
Tudor–Eliade Ciuleanu 11.7k 1.1× 12.7k 1.5× 2.7k 0.4× 3.9k 0.8× 1.2k 0.7× 201 17.3k
Filippo de Marinis 14.7k 1.3× 13.4k 1.6× 2.7k 0.4× 4.0k 0.8× 874 0.5× 450 18.9k

Countries citing papers authored by Geoffrey R. Oxnard

Since Specialization
Citations

This map shows the geographic impact of Geoffrey R. Oxnard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Geoffrey R. Oxnard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Geoffrey R. Oxnard more than expected).

Fields of papers citing papers by Geoffrey R. Oxnard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Geoffrey R. Oxnard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Geoffrey R. Oxnard. The network helps show where Geoffrey R. Oxnard may publish in the future.

Co-authorship network of co-authors of Geoffrey R. Oxnard

This figure shows the co-authorship network connecting the top 25 collaborators of Geoffrey R. Oxnard. A scholar is included among the top collaborators of Geoffrey R. Oxnard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Geoffrey R. Oxnard. Geoffrey R. Oxnard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Loading papers...

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julie Bernhardt Breakdown of academic impact, for papers by Mark I. McCormick Breakdown of academic impact, for papers by John Monahan Breakdown of academic impact, for papers by David Bacon Breakdown of academic impact, for papers by Yae Kanai Breakdown of academic impact, for papers by Thomas Illig Breakdown of academic impact, for papers by Javier DeFelipe Breakdown of academic impact, for papers by S. Thayumanavan
Rankless by CCL
2026